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Abstract: Colorectal carcinoma (CRC) is the third most common cancer. Likewise, it is a disease
that has a long survival if it is prematurely detected. However, more than 50% of patients will
develop metastases, mainly in the liver (LM-CRC), throughout the evolution of their disease, which
accounts for most CRC-related deaths. Treatment it is certainly a controversial issue, since it has not
been shown to increase overall survival in the adjuvant setting, although it does improve disease
free survival (DFS). Moreover, current chemotherapy combinations are administered based on data
extrapolated from primary tumors (PT), not considering that LM-CRC present a very particular
tumor microenvironment that can radically condition the effectiveness of treatments designed for
a PT. The liver has a particular histology and microenvironment that can determine tumor growth
and response to treatments: double blood supply, vascularization through fenestrated sinusoids and
the presence of different mesenchymal cell types, among other particularities. Likewise, the liver
presents a peculiar immune response against tumor cells, a fact that correlates with the poor response
to immunotherapy. All these aspects will be addressed in this review, putting them in the context of
the histological growth patterns of LM-CRC, a particular pathologic feature with both prognostic
and predictive repercussions.
Keywords: histologic growth patterns; desmoplasia; carcinoma-associated fibroblasts; microenviron-
ment; liver; hepatic stellate cells; capsule
1. Introduction
Colorectal carcinoma (CRC) is the third most frequent tumor in the world and the
second in Europe. Taking both sexes into account, there are 1,850,000 new cases annually
worldwide [1]. The incidence of this tumor increases by 2% each year and it is the primary
cause of death due to cancer. The annual number of deaths is approximately half that
of the incidence (880,000 deaths worldwide in 2020). Therefore, tackling this disease is
one of the highest priority challenges in healthcare. Despite the best survival results with
adjuvant chemotherapy since the publication of the MOSAIC study [2], approximately
20% of patients will develop metachronous metastases in the liver in less than three
years following resection of the primary tumor and 25% displayed liver metastases at
diagnosis (synchronous) [3]. In liver metastases from CRC (LM-CRC), curative surgery
is the treatment of choice if it is performed in specialized centers. However, in these
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advanced stages of the disease, the 5-year survival rates are less than 10%. Although
only about 15% of metastases are initially resectable, this percentage can reach 30% if
conversion chemotherapy is administered to selected patients. In the past few years,
many treatment advances, such as more effective chemotherapy or staged hepatectomies,
have emerged. However, despite the curative intent, there is a high rate of intrahepatic
recurrence. Moreover, despite the fact that many retrospective studies have identified poor
prognostic factors such as tumor size or number of lesions [4], none of them provide enough
information to take surgical decisions. This fact highlights the need for new prognostic
factors to select the best therapeutic approach for each patient.
In addition, a few advances in preclinical research have been translated into significant
benefits, either in clinical terms or with respect to the quality of life of patients with LM-CRC.
Despite important preclinical discoveries about aberrant biological pathways associated
with the development and progression of the primary tumor, certain pathological aspects
of the formation of liver metastases remain unknown.
A very common approach to study the biology of the metastatic process has been
to compare the primary tumor and the metastatic lesions. Although great similarities
between both tumors have been described at the genomic level [5], at the transcriptional
level, relevant differences that reflect the particular microenvironment of each different
location have been determined. The liver, to name a few examples, has exclusive stromal
cells at this location, e.g., Kupffer cells, hepatic stellate cells (HSC) and portal fibroblasts
(PF). Due to the great influence of the microenvironment on both the tumor biology and
the response mechanisms to chemotherapy and targeted therapies, this fact should have a
determining impact on the clinical management of patients with LM-CRC compared to
patients without distant lesions.
Moreover, LM-CRC present different histological characteristics that accentuate their
morphological differences from primary colorectal tumors. Thus, a remarkable presence of
cancer-associated fibroblasts (CAFs), constituting the main stromal cell type and reaching
75–80% of the entire tumor mass, high interstitial pressure that hampers the delivery of
drugs and a defective immunologic response from the host are essential to understand
the therapeutic resistances of LM-CRC. Even considering possible therapeutic strategies
focused on stromal cells, we must bear in mind that fibroblasts demonstrate certain to-
pographic differentiation [6]. This means that the CAFs of a primary tumor may present
different characteristics to the CAFs of a liver lesion [7,8] in the same patient, and therefore
therapies designed against colonic CAFs may not be efficient enough over hepatic CAFs.
On the other hand, liver metastases have displayed a unique histologic feature, a histologic
growth pattern (HGP) [9], that will be described in more detail in the next section (Figure 1).
Interestingly, these HGPs displayed prognostic [10,11] and predictive [12] value, suggesting
that possibly intratumoral CAFs and peritumoral CAFs are exerting different functions
that could be a consequence of either different origins or different cellular precursors, or
particular responses of the host against the tumor type.
Thus, the tumor microenvironment in liver lesions presents unique and differential
characteristics that are going to be highly relevant in the management of the patients. In
the following sections, we will elucidate the relevance of the different cell types that shape
up the liver microenvironment, the way in which they are structured, the altered immune
response and the clinical and therapeutic consequences that can be derived from them.
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Figure 1. Hematoxylin and eosin staining of histologic growth patterns (HGPs) of liver metastases
from colorectal cancer (LM-CRC). (A,B) encapsulating/desmoplastic, (C,D) invasive/replacement,
and (E,F) expansive/pushing, the different HGPs at low magnification. In the right column, same
patterns at detailed magnification.
2. Histology of LM-CRC
As mentioned before, LM-CRC are characterized at the histological level by their
way of growing and infiltrating liver parenchyma. It is widely accepted by the scien-
tific community that there are three main HGPs named “pushing”, “replacement” and
“desmoplastic”, which were described for the first time in 1996 (including a fourth subtype,
sinusoidal) [13], although the terminology was finally coined in 2001 [14] (Figure 1). The
“desmoplastic” HGP is also named “encapsulated” and its most important feature is that
tumoral cells are separated from liver parenchyma by a fibrotic stromal capsule; thus,
tumoral cells and hepatocytes never touch. Conversely, in the “replacement” subtype,
there is a direct contact between hepatocytes and tumoral cells. In “replacement” HGP, also
called “invasive”, tumor cells infiltrate liver parenchyma, replacing the hepatocytes and
following the hepatic sinusoidal structure, which makes it difficult to clearly distinguish
the tumor border [15]. Finally, in the “pushing” or “expansive” HGP, tumoral cells literally
“push” the hepatocytes, which become flattened in consequence, and the tumor border is
clearly demarcated, but no fibrotic tissue intervenes. However, there is no direct contact
between hepatocytes and tumor cells.
The relevance of these distinct HGPs falls in their possible utility as a prognostic
and predictive tool, due to its numerously described association with tumor recurrence
and overall survival [10,16–18] as well as prediction of response to anti-angiogenic ther-
apies [12]. On this matter, patients who present a predominantly desmoplastic growth
pattern have superior survival after resection with curative intent when compared with
patients presenting the replacement type [9–11,16,18,19]. Although a significant percentage
of patients present a mixed pattern, with dHGP and non-dHGP areas, the most favorable
prognosis is in those patients who present a pure dHGP pattern, complete throughout
the entire liver–tumor interface [10]. Interesting, prognosis has also been related to the
thickness of the capsule: the thicker the capsule, the better the prognosis [20].
These differences in survival could partially rely on the fact that, in the desmoplastic
growth pattern, there is a band of stroma enriched in collagen and with dense lymphocytic
infiltration that may act as a physical obstacle for the tumor expansion. This is particularity
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emphasized by an increase in collagen type IV and integrin blockade, which reduces the
infiltration capacity of tumoral cells through liver parenchyma [14,18].
In this line, the differences in recurrence rates could be explained by the HGP surgical
implications. For mCRC, liver resection is the gold standard therapy, with a curative aim.
The success of this therapy is closely related to the percentage of R0 resections achieved. It
has been described that desmoplastic patterns are associated with an increased rate of R0
(tumor-cell-clean resection margins), probably because the stromal tissue surrounding the
metastases protects against a margin-positive resection. Therefore, a resection with a more
extended margin could benefit replacement and pushing cases [21].
Interestingly, HGPs have also been described in liver metastases from other types of
cancer such as uveal melanoma [22,23], gastric cancer [24] and breast cancer [25], which
adds interest to the predictive value of HGPs. However, because hepatectomy is less
common in these cases, the prognostic role of HGPs is much less explored [21].
The lung is the second most common place where CRC metastasizes [26]. In fact,
three different HGPs have also been described in CRC lung metastases. First, a pushing
pattern, where tumoral cells compress pulmonary parenchyma. Second, a desmoplastic
pattern, which also shows a desmoplastic rim containing immune infiltrates. Finally, third,
an aerogenous pattern that can be considered as the analogue to the replacement pattern in
liver as the tumor cells spread in the pulmonary air spaces without disrupting the lung
architecture [27]. These HGPs observed in lung metastases also have clinical meaning, and
the aerogenous pattern displays a poor prognosis, which concurs with liver replacement
HGP as well. The brain is another organ where three metastatic patterns have been reported:
a well-demarcated one, vascular co-option and diffuse infiltration; however, their impact
on overall survival could not be assessed in autopsy studies [28]. Therefore, HGPs could
have a role in guiding therapeutic decisions in many different contexts apart from LM-CRC.
This also implies the need for predicting the HGP on different imaging modalities.
Another aspect to consider is how preoperative neoadjuvant treatment received by a
proportion of patients with LM-CRC could affect the HGP and the ratios of cells that constitute
the metastatic tumor microenvironment (TME). Concerning this, it has been described that in
neoadjuvantly treated patients, the percentage of dHGP is higher. However, further investiga-
tion is needed, as most of the studies that attend this issue englobe different chemotherapeutic
regimens [10]. Moreover, it has been reported that some features, such as the expression of a
plasminogen receptor or the presence of CD68+ macrophages, differ between desmoplastic
and non-desmoplastic HGPs but not in neoadjuvantly treated patients [29]. Thus, neoadjuvant
chemotherapy is altering tumor growth in many different aspects, the study of which could
be crucial for the development of better treatment strategies.
Taken together, HGPs are not only a distinct morphological feature of LM-CRC, but
also a valuable prognostic marker. HGPs also reflect the biological processes underlying
tumor growth. Moreover, therapy-induced conversion of non-dHGP into dHGP would
improve the survival for the patients with metastatic disease dramatically. The develop-
ment of such treatment, however, requires better understanding of the biological processes
underlying metastatic growth.
3. Biology of LM-CRC
From a biology perspective, the mode through which metastases grow in the liver
has awaked high interest as it should conceal the mechanisms underlying the previously
described differences in prognosis. First, it is important to take into account that the
progression of liver metastases consists of four phases, proposed for the first time by
Vidal-Vanaclocha in 2011 [30], in which the hepatic microenvironment can play opposing
roles [31]. The first one, called the microvascular phase, occurs in sinusoidal vessels
when circulating tumor cells arrive [31,32]. At this timepoint, cancer cells need to be able
to attach and adhere to the endothelial cell layer and, eventually, transmigrate through
the vascular endothelium. This complex process is called extravasation and leads to the
following second phase: pre-angiogenic or intra-lobular micrometastatic phase. In this
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phase, stromal cells from liver and immune cells are recruited, but the micrometastases
still do not show vascularization. In the third angiogenic or pan-lobular phase, the hypoxic
microenvironment induces the recruitment of endothelial cells and formation of blood
vessels. Finally, in the fourth lobar growth phase, the new tumor can be clinically detectable.
The progression of these phases and the following growth of the metastasis depend on the
interactions that occur between malignant cells and the liver microenvironment [31,32].
Thus, this process can be assessed in two ways. The local microenvironment can be
considered as the major determinant of the host reaction on the tumor progression. In
this case, the host tissue defines the development of a certain HGP and thus contains the
key for explaining worse or better outcome. On the other hand, metastasized cancer cells
interact with the different host cell types and, through the paracrine signaling, transform
host stroma and determine HGP development. However, up to now, the formation of a
particular HGP is still an unknown process, and there are no clues for a tumor-driven
or a host-driven mechanism. A concept proposed by Fernando Vidal-Vanaclocha [33]
distinguishes at least three different “entry points” for the cancer cells and thus three
different metastatic niches which shape up the tumor–host interaction and drive the
evolution of the tumor: periportal, perisinusoidal and intrasinusoidal. According to this
concept, cancer cells which enter periportal and perisinusoidal spaces develop according to
the “classical” process, following four phases, as described above. During the intra-lobular
and pan-lobular phases, malignant cells invade parenchymal cell plates (perisinusoidal
location) or the portal space (periportal location) and develop a pushing–desmoplastic
phenotype, while intrasinusoidal metastases start proliferation already in the intravascular
space, avoiding the extravasation phase. These metastases develop in a very distinct
microenvironment, surrounded by liver sinusoidal endothelial cells (LSEC) and elements
of the blood, which require different surviving mechanisms. During further growth,
intrasinusoidal micrometastasis disrupts the sinusoid and develops a replacement HGP.
However, these processes have not been experimentally demonstrated so far.
Concerning the host microenvironment, the liver harbors different stromal cells, which
include host macrophages (Kupffer cells), host fibroblasts (HSC and PF), LSEC, liver-
associated lymphocytes and dendritic cells [31,32]. Moreover, there are also circulating and
bone marrow-derived immune cells that are recruited in response to the malignant growth.
These host cells, as well as the recruited cells of the immune system, interact in a complex
interplay of cytokines and chemokines that conform to the microenvironment in which the
metastatic tumor growth takes place.
3.1. Liver Sinusoidal Endothelial Cells (LSEC)
LSEC play a crucial role, as they are the first host cells to be in direct contact with
tumoral cells. LSEC are part of the first line of defense, also accompanied by Kupffer
cells and hepatic natural killers, which may destroy tumor cells through the release of
pro-apoptotic signals prior to extravasation [31,34]. However, LSEC can also promote
attachment and adherence of the cancer cells by expressing cell surface adhesion molecules
(CAM), thus facilitating metastasis formation [31]. Moreover, LSEC secrete fibronectin,
which can induce an epithelial–mesenchymal transition in cancer cells, and macrophage
migration inhibitory factor [35,36]. In addition, LSEC can also be a key player for HGP
development as they are closely related to the metastasis vascularization pattern [31,37–39].
Finally, LSEC are endocytic cells that scavenge molecules from the bloodstream and
present them to hepatic lymphocytes, which leads to a physiological immune regulation
towards tolerance preventing liver parenchymal damage. However, during hepatic metas-
tasis development, tumor-activated LSEC become highly inflamed which fosters their
immune suppressive effect, especially in the replacement HGP [27]. As shown in an experi-
mental model of hepatic CRC metastasis, the mechanism is contributed by IL-1-induced
LSEC mannose receptors [40].
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3.2. Cancer-Associated Fibroblasts
As it happens in primary tumors [8], LM-CRC are characterized by desmoplasia,
which is defined as the presence of a high amount of stroma among the malignant cells.
This reactive stroma creates the proper environment for tumor development and CAFs
are the main component of it. In a desmoplastic TME, CAFs interact with the extracellular
matrix and with the other cells and mediate processes that favor tumor cells: promoting
tumor cell proliferation and migration, supporting stem cell niche generation, regulating
immune suppression and influencing chemoresistance.
In general terms, fibroblasts in physiological conditions remain in a quiescent state
and become activated in case of tissue damage. Similarly, CAFs are fibroblasts that have
been activated by the interaction with tumor cells. This activation implies morphological
changes and the expression of a plethora of CAFs markers, such as α-smooth muscle actin,
periostin and fibroblast activating protein (FAP). This marker expression pattern changes
markedly depending on the CAFs’ location both inside the tumor and in their anatomic
demarcation [7]. Once they are activated, CAFs generate the collagens and fibronectin
that conform to the extracellular matrix, as well as crosstalking with tumor cells through
cytokines and growth factors [41].
Moreover, in different types of cancer, the quantity of CAFs is associated with bad
prognosis [42–44]. However, the existence of different CAF subpopulations associated with
different functions has been demonstrated [45,46]. Thus, they have to be considered as
heterogeneous cells and the biomarkers to characterize these different subpopulations need
to be defined [8,47,48].
In addition, CAFs also play an important role in the process of chemoresistance [49].
They can create a physical barrier that hinders the drugs to reach the tumor cells or alter
drugs’ function through factors production [50–52].
For all these reasons, CAFs are considered to be a potential therapeutic target for
desmoplastic tumors. Therefore, many research groups have focused on developing
therapeutic strategies for the elimination of CAFs, which have shown opposite effects.
Thus, the inhibition of CAFs’ functions had a positive effect on sensitizing tumoral cells to
treatments [48,53–55]. On the contrary, other studies have shown that CAF depletion can
also result in a protumoral effect [53]. Therefore, this further suggests the coexistence of
different CAF subpopulations associated with different functions [53].
In the context of LM-CRC, the function of CAFs remains unclear. However, as these
metastases have been shown to grow in different HGPs associated with prognosis, CAFs
located in particular topographic areas of the tumor, e.g., peritumoral/encapsulating CAFs,
CAFs in invasive margins or CAFs in central tumoral areas, might be playing different
roles and probably reflect different temporal processes (Figure 2).
In other types of cancer, such as pancreas [56], breast [57] and lung cancer [58,59], dif-
ferent subpopulations of CAFs have already been described. These publications highlight
the fact that CAFs may change from one state to another depending on the context [60].
Other authors have classified CAFs according to their spatial location in pancreatic tumors,
having observed a particular transcriptional signature at each location [61]. Despite these
results, clearly more research is needed to elucidate the most accurate classification and
association of particular subsets with functionality and spatial location.
Taking together, these data provide evidence that there may coexist subpopulations
of CAFs performing both tumor-supportive and tumor-suppressive functions. These
subpopulations can be shaped up by multiple factors such as the location inside the tumor,
the origin of the CAF and the effect of chemotherapy and may vary between different
tissues and anatomic demarcations. In this line, characterizing the degree of fibroblast
heterogeneity as well as the dynamics of the different biomarkers would provide highly
valuable tools to design new therapeutic strategies.
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Figure 2. Different cancer-associated fibroblast (CAF) subsets might be topographically located in
particular areas inside the LM-CRC. Although it is a fact that should be explored in detail with
dedicated technologies such as spatial transcriptomics, invasive margins (A–D) displayed an intense
staining of both αSMA and FAP. The outer regions of the liver metastases are those areas where
there is a constant tissue remodeling and where tumor cells show more aggressive phenotypes,
higher proliferation and migration capabilities. On the contrary, in central areas of the tumor (E–H),
having the liver–tumor interface as a reference, a progressive decrease in FAP staining is observed,
becoming negative in the most central and internal areas of the tumor. The staining of αSMA is
quite homogeneous. These areas usually correspond to areas of secondary fibrosis enriched in
myofibroblasts, probably corresponding to myCAFs. These areas are progressively repaired as the
tumor grows. In these areas, the activation pattern of CAFs is different from those closest to the
invasive margin (rHGP stands for the replacement histologic growth pattern).
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Concerning the stromal reaction of the three HGPs, they can be simplified in two
groups, the ones which show a fibrotic rim, the desmoplastic HGP (dHGP), and the ones
that do not (non-dHGP). In this context, three different topographic locations of CAFs can
be distinguished. First, CAFs present in the fibrotic rim of the dHGP, i.e., in peritumoral
stromal areas. Second, CAFs located at the invasive margin, i.e., intratumoral CAFs located
in outer tumoral areas. As the prognoses differ drastically in metastases that show 100% of
dHGP, it may be plausible that peritumoral and intratumoral fibroblasts near to the host–
tumor interface are different subsets with different functions, or particular juxtacrine and
paracrine crosstalk with tumor cells might induce phenotypic differences with functional
consequences (Figure 2). Third, intratumoral CAFs located in central tumoral regions,
common for the different HGPs. These areas usually present large extensions formed
mainly by myofibroblastic CAFs and extracellular matrix components and are often related
to secondary fibrosis processes. These are areas where CAFs do not usually express FAP or
other inflammatory CAF markers. In colloquial terms, we could say that these are areas
where the battle between the tumor and the host has already ended—areas of injury that
must be repaired.
The fibrotic rim of the dHGP is considered by many authors as a response to the
inflammation and damage in the host tissue to the growing tumor. Moreover, the link
between the presence of the desmoplastic capsule and a considerable better prognosis
makes it possible to hypothesize that these CAFs play a tumor suppressor role, limiting
physically and chemically the tumor growth and attracting immune infiltrates to act against
malignant cells.
A few results seem to indicate that the fibrotic rim could be acting as a defensive
barrier. First, the capsule could be mechanically acting as a protective shield avoiding local
spreading. Second, it might be acting as a chemical barrier. Lunevicius et al. [62] described
that the inner side of the capsule was enriched in collagen fibers and fibroblastic cells
negative for metalloproteases. In contrast, the outer portion of the capsule was formed by
cells expressing matrix metalloproteins (MMPs). In a similar vein, Illemann et al. [63] also
described a difference in the cellular composition of the capsules, with the outer portion
being enriched in αSMA-positive CAFs. What we observed in our laboratory is a certain
gradient of positivity for some characteristic CAF markers. As summarized in Figure 3,
we observed that the outer part of the capsule, the half side in contact with hepatocytes,
is enriched in αSMA-expressing cells, while the inner part, in contact with tumor cells, is
enriched in FAP-positive CAFs.
This gradient was also observed for periostin, fibronectin and podoplanin, which
indicates that a certain differential degree of activation or a differential cellular composition
could be occurring (Figure 4).
The differences observed in terms of the differential expression of certain proteins in
the fibrotic rim raises the controversy whether this fact is due to the presence of different
types of CAFs depending on their location in the capsule. In turn, the coexistence of
different CAFs could imply that each of them came from a different precursor, a fact that
has yet to be demonstrated. Another possibility is that it is a single cell type with high
plasticity, as a consequence of the influence of tumor cells on the inner half of the capsule.
However, defining the origin of activated myofibroblasts is one of the major challenges
of the research on fibrosis, as those cells might be potential therapeutic targets against
this remodeling process. In addition, several fibroblastic cells have been defined in the
human liver [64]. In animal models, many different fibroblast origins have been also
identified. Fibrocyte invasion, endogenous resident fibroblasts, pericytes and gli1-positive
mesenchymal stem cells would be some examples. In the context of cancer, it is also a
recurrent aspect to focus on, especially in the desmoplastic kind of tumor. This is the
case of pancreatic cancer, where the two major stromal sources are resident pancreatic
fibroblasts and stellate cells. In breast cancer, CAFs are thought to derive from pericytes,
resident fibroblasts and even from the transformed epithelial cells via EMT. Thereby, the
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origin of CAFs, as well as the origin of myofibroblasts in fibrosis, varies depending on the
tissue [57,65].
Figure 3. The fibrous capsules of liver metastases present CAFs that express different biomarkers
classically associated with the activation of these cells. This fact enables two hypotheses, pending
to be proved. On the one hand, it could be that different subpopulations coexisted in the same
peritumoral area. On the other hand, it could be the same cells, which, depending on their proximity
to the tumor cells, could establish a paracrine crosstalk with them, which would modulate the
phenotype of the CAFs. The two columns of images correspond to two different encapsulating
tumors, where positive αSMA CAFs (green immunofluorescence) are observed in the outer area
of the capsule, the one closest to the liver parenchyma. On the contrary, in the inner area, αSMA
positivity progressively disappears, while FAP-expressing cells (red immunofluorescence) appear as
fibroblasts approach tumor cells. The FAP protein has two main locations, as a protein anchored to
the plasma membrane, or as a component of the extracellular matrix (ECM). In some publications, it
has been mentioned that fibrous capsules are formed by fibroblasts on their outermost layer and by
acellular components on their innermost layer, mainly ECM components. However, DAPI staining
indicates the presence of elongated nuclei that are compatible with the existence of CAFs in the
deeper areas of the fibrous capsule.
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Figure 4. Immunohistochemical staining of a desmoplastic liver metastasis from CRC. We used
classical markers for carcinoma-associated fibroblasts (αSMA, FAPα and S100A4). As shown in the
microphotographs, the outer half of the capsule stains for αSMA-positive fibroblastic cells, while the
inner half does it for FAPα, as also shown in Figure 3. We did not observe staining for S100A4 (also
known as FSP1, Fibroblast Specific Protein 1) on cells of the capsule. Podoplanin, which is a type 1
integral membrane glycoprotein and is characteristic of particular CAF subsets, also stains in cells of
the inner half of the membrane, as is the case for various proteins of the extracellular matrix, such as
fibronectin and periostin (among others, not shown).
In the context of LM-CRC and fibrotic diseases of the liver, the three main sources de-
scribed are resident mesenchymal cells, which include quiescent HSC and resident PF, but
we cannot exclude other cells that have undergone EMT (hepatocytes, cholangiocytes and
endothelial cells), and bone-marrow derived cells, consisting of fibrocytes and circulating
mesenchymal cells. However, the origin of myofibroblasts may be different depending on
the liver disease that causes the fibrosis [66].
In LM-CRC, many cell types have been discussed to contribute to the stromal reaction,
such as smooth muscle cells or circulating mesenchymal cells. However, as currently
considered, the main CAF sources in the liver are HSC, PF [67] and fibroblasts surrounding
the centrolobular vein, the so-called second-layer cells [68].
HSC are in the space of Disse, around the sinusoidal LSEC, and represent 5% to 8%
of the liver cellular population. In normal conditions, they are characterized for being
in a quiescent state and containing lipid droplets with vitamin A [68]. Once activated,
HSC acquire myofibroblast features such as αSMA expression and extracellular matrix
deposition and become the orchestrating cells of the liver injury response [69]. In vitro,
these cells have been reported to be able to undergo myofibroblastic transdifferentiation [70].
In hepatic metastases, HSC release growth factors and metalloproteinases and deposit type
I and IV collagens and laminin [31]. They are also involved in endothelial cell recruitment
and neoangiogenesis [71], as well as in tumor cell invasion and proliferation [31]. On the
other hand, PF can also be the origin of CAFs when cancer cells are located in portal tracts,
but they probably initiate the stromal response through a different process.
Finally, another origin that has been explored are hepatocytes located at the periphery
of the metastases, which can undergo EMT and contribute to fibrosis and angiogenesis [70].
In the context of HGP and spatial localization, the different types of CAFs lead us
to question which cell type is the precursor of fibrotic capsules or if is it a mixture of the
cell types described above. In this sense, we can learn a lot from the research carried out
on fibrotic liver diseases, which will probably follow processes similar to liver tumoral
malignancies. Therefore, it is crucial to know in detail the differences between HSC and
PF, especially in the context of the activation of both cell types. This can also be affected
by the route of entrance of the tumor cell into the liver, that is, whether it extravasates
in a centrolobular vein, in a portal tract or directly into a sinusoid. It has been observed
in experimental models of fibrosis that depending on the etiology, there is a differential
activation of both HSC and PF. For example, HSC are the main source of myofibroblasts in
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lesions induced by Tetrachloromethane (CCl4), whereas PF are the main source in lesions
induced by bile duct occlusion [72]. Likewise, the differences between activated HSC and
activated PF have been characterized, and some characteristic biomarkers of each cell type
have been reported once they have undergone an activation process. It has been described
that PF are characterized by the expression of CD90, while activated HSC would be negative
for this marker [73]. On the contrary, cytoglobin has been described as a good characteristic
marker of activated HSC and that it is not expressed in activated PF [74]. What seems very
plausible is that CAFs from different origins coexist in LM-CRC. Data from our laboratory
reinforce this fact, since we isolated CD90-positive CAFs and CD90-negative CAFs that
could correspond to a differential origin or precursor (data not shown).
However, we cannot rule out that the generation of the capsule is due to intrinsic
properties of the tumor cell. In any case, they are important aspects that must be taken into
account because they could provide future therapeutic strategies.
Therefore, all this knowledge leads us to speculate that each HGP contains CAFs
coming from a distinct origin among those earlier described. This would be in line with
the hypothesis on the HGP predetermination by the different access routes of circulating
tumor cells into hepatic tissue [30]. On the one hand, if tumoral cells enter through a portal
tract, they would first interact with PF and those would mediate the stromal reaction. On
the other hand, if they reach hepatic sinusoids, they will be able to activate HSC and the
process of fibrosis would be orchestrated by them [75,76].
3.3. Tumor Vascularization
Different HGPs have also been associated with different types of tumor vasculariza-
tion. In fact, another common classification for HGPs considers only two patterns: the
angiogenic, which includes desmoplastic and pushing HGPs, and the non-angiogenic one
that refers to the replacement HGP [27].
In the replacement HGP, the tumoral cells benefit from the hepatic architecture: they
progressively “replace” the hepatocyte plates and use the already existing connective tissue
and blood vessels. Hence, tumor vascularization is carried out by a non-angiogenic process
called vessel “co-option” [12,14,25]. On the other hand, in desmoplastic and pushing
HGPs, the tumor completely disturbs the hepatic architecture, creating its own supporting
stroma, new blood vessels through an angiogenic process and, in the dHGP, forming the
desmoplastic rim that separates the tumor from parenchyma. As an effect of vascular
endothelial growth factor (VEGF), these new angiogenic blood vessels are composed by
proliferating endothelial cells and form what is called “vascular hot spots”. Moreover,
as they are not covered by pericytes, VEGF also induces the deposition of fibrin in a
perivascular space [16,25].
Some studies have suggested that these different tumor vascularization types can
be related to the route that tumoral cells take during the extravasation phase. In this
line, a study performed with a murine model found that, if the cancer cells had invaded
between LSEC in the space of Disse [75], the metastases with a co-option sinusoidal system
developed. On contrary, as showed in the other study, if tumoral cells were injected via the
portal route, near the portal tracts, they demonstrated the development of an angiogenic
pattern [76]. However, at the moment, further investigation is needed to prove this fact.
This might explain why the patients with a replacement (presumably non-angiogenic) HGP
obtain less clinical benefit from bevacizumab-chemo treatment, which is a VEGF inhibitor,
when compared with the patients with desmoplastic (angiogenic) metastases [27]. This
concept may explain the failure of anti-angiogenic therapy in breast cancer liver metastases,
which predominantly show the replacement HGP [12].
Thus, the tumor vascularization strategy used by each HGP is another feature to con-
sider in order to understand their biological processes and finally select the best treatment
option in each case.
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3.4. Immune Infiltrates
The immune system plays crucial role in controlling tumor growth and dissemination.
With the introduction of immune checkpoint inhibitors (ICI) into clinical practice, the
interest of the research community in the tumor immune microenvironment has been raised
and a growing body of preclinical and clinical studies has been accumulated. With this
background, the immune microenvironment of LM-CRC has not been fully investigated.
In 2018, Pagès et al. [77] reported a study based on 603 resected synchronous and
metachronous metastases from mCRC patients. When compared to primary tumors,
metastases were characterized by higher levels of CD3, CD8 and CD45RO lymphocytes
and lower levels of CD20 cells, while the FoxP3-positive cell count did not demonstrate
a difference. This observation, however, was based on either hot spot analysis or the
whole slide average immune cell count and did not consider the spatial context. A certain
pattern was observed in relation to the size of the metastasis and lymphocyte infiltration:
the average infiltration was higher in small metastases; however, larger-size lesions often
had “hot spots” with very high lymphocyte density, not observed in small tumors. This
pattern was also seen when analyzing small and large metastases in patients with multiple
metastases. Importantly, although the average lymphocyte density did not differ between
cases with different metastatic burdens, the individual lesions in patients with multiple
metastases demonstrated significant heterogeneity with regard to immune density. This
observation is in consistence with earlier work of Halama et al. [78] performed with a
focus on partially different immune cell subsets (CD3+, CD8+ and granzyme B+ cells) and
overall may suggest that the tumor-related factors are more important for the local immune
response than individual variations in the immune background of the host organ. However,
Brunner et al. [79], although based on very few samples (n = 5), reported a conflicting
observation, i.e., the homogeneity of immune infiltration patterns (CD4, CD8, CD45RO)
between different lesions in patients with multiple metastases.
Immune infiltration is not evenly distributed in liver metastases. Thus, peripheral
regions of the metastases have higher infiltration of CD3, CD8, C45RO and CD20 lympho-
cytes [79–82] and probably of NKp46+ cells [82] in comparison to the central regions of
the lesion. Further, peripheral regions have higher infiltration of CD4, CD45RO and CD8
cells in comparison to distant peritumoral liver parenchyma [79]. However, the definition
and extent of the peripheral region (or invasive margin) of the metastases are not set up
and vary between the studies. For example, sometimes, such peripheral region contained
marginal tumor tissue, and other times, it was defined as a peritumoral, non-malignant
zone of a certain depth. Attempts for more detailed spatial analysis are rare and until now
are limited to very few samples [78].
What is even more important in the contexts of the current review is that the above-
mentioned studies did not adjust the scoring technique according to different HGPs and
almost never considered the HGP in reports. However, the evaluation of inflammatory
infiltrates in the context of HGPs is of crucial importance, since they topographically
delimit structures that end up being physical and chemical barriers to infiltration by these
cells. Concerning intratumoral regions, FoxP3, CD79A and Kappa/Lambda were more
frequent in dHGP according to Höppener et al. [79]. Importantly, only intraepithelial, but
not stromal, CD8 cells demonstrated such difference.
A few studies investigated peritumoral tissue. Thus, Brunner et al. reported that high
levels of CD4, CD45RO and CD8 in the near peritumoral region (when normalized to im-
mune infiltration in distant peritumoral regions) were associated with the dHGP [79]. This
was further developed by Höppener et al. [83], who showed higher counts for CD8, CD45,
CD79A, Kappa/Lambda and SLAMF7 cells in peritumoural areas of dHGP CRLMs in
comparison to the rHGP. At the same time, FoxP3 cells did not demonstrate such difference.
Digital image analysis on an independent tissue set confirmed the results for CD8 cells but
also revealed the same association for FoxP3 cells (higher in the peritumoral dHGP). These
in situ analyses did not reveal a difference in CD4 infiltration, but flow cytometry demon-
strated a relative increase in CD4+ cells within the band of CD3+ T lymphocytes in the
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non-dHGP. Authors speculated that such effect must be due to an increase in CD4+FoxP3-
helper cells because no difference was found for Tregs (CD4+FoxP3+). Interestingly, even
in individual metastases with a combination of HGPs, a high density of CD8 cells is seen in
the area of the dHGP while being very low in the regions of the rHGP [27].
The concept based on the different spatial patterns of the immune response was
developed in recent years. Thus, tumors demonstrating high lymphocyte infiltration
were designated “inflamed” or “hot”, while tumors with a low immune cell content were
classified as “desert” or “cold” tumors [84]. The third category of tumors was characterized
by high abundance of immune cells, which, however, do not penetrate cancer cell nests
but are instead retained in the stroma. This phenotype was termed “immune-excluded”.
Interestingly, immune infiltration in “immune-excluded” tumors may be limited to the
peritumoral stroma or capsule (if present) but may also infiltrate the tumor itself and
stay retained in intratumoral stromal bulks [84]. We believe that these two types of
“immune-excluded” phenotype may be characterized by qualitative differences in the
existing antitumor response and by different mechanisms of the blockage of immune cells.
The important observation regarding lymphocyte infiltration in the dHGP of LM-CRC is
that the majority of lymphocytes accumulate at the interface between the outer part of
the desmoplastic rim and the adjacent liver parenchyma [27]. Most immune cells, thus,
although present in a high number, are kept at a distance from the malignant tissue. Due
to such an immune phenotype, Jan van Dam [27,85] suggested considering metastases
with the dHGP as “immune-excluded” tumors. However, some other reports considered
an association of the dHGP with an inflamed phenotype [86]. In the rHGP, lymphocytes
are present in the interface between liver parenchyma and the tumor and thus directly
approach malignant cells, although being in relatively low numbers. We believe that
a certain level of the confusion and discordance in results is caused by several reasons.
First, different immune cells and different visualization methods may capture distinct
lymphocyte subclasses with potentially different biology. Second, the absence of proper
definitions for the immune phenotypes. Third, a lack of standardized criteria for the
assessment and reporting of the spatial immune cell distribution in different HGPs.
It remains a question as to why there is such a lack of an immune-competent response
from the liver tumor microenvironment [86]. However, different cells can contribute to
such unresponsiveness. Thus, cancer-associated fibroblasts can express PD-L1 [87–90] or
may induce its expression in other cells [82–84], contributing to immunologic silencing.
Particular CAF subtypes can also induce the expression of PD-1 and CTLA4 in surrounding
lymphocytes [88–91], contributing to immunosuppression and resistance to immunother-
apy. Liver endothelial sinusoidal cells can also induce T cell exhaustion and suppress innate
responses [92]. Kupffer cells [93] and HSC [93] contribute to such hypo-reactivity. How-
ever, the balance between responsiveness or unresponsiveness seems to be predetermined
according to the HGP.
The overall impact of the prognostic role of immune infiltration was recently summarized
elsewhere [94]. Despite heterogeneous study designs, cells of interest and scoring criteria, a
clear overall trend with high intratumoral infiltration of CD4, CD8 or CD45RO and improved
survival could be stated. Interestingly, out of nine studies, six considered peritumoral regions
as of separate interest; however, none of them distinguished HGPs. The prognostic impact of
immune cell infiltration in peritumoral regions is not clear. To the best of our knowledge, only
one study evaluated both HGPs and immune phenotypes of LM-CRC with regard to survival.
In this study, Stremitzer et al. classified 118 metastases into an inflamed immune phenotype
and a non-inflamed immune phenotype, based on CD8-positive cell infiltration [86]. The
inflamed immune phenotype was associated with the dHGP and both of them were linked to
improved survival. Unfortunately, the survival differences between all three groups and their
distribution across HGPs remained unreported.
Studies have demonstrated that patients with MSI-H cancer, which develop dis-
tant metastases, may benefit from immunotherapy [95,96]. These results led to FDA
approval for ICI pembrolizumab and nivolumab for the treatment of chemoresistant MSI-H
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(microsatellite-instability high) metastatic CRC. Despite pioneering studies of the Galon
group [80,97,98], the dynamics of the immune microenvironment under immunotherapy
in metastatic lesions remains unclear.
Thus, LM-CRC can have different immune infiltration patterns. The crude rate of
lymphocyte immune infiltration in the resected metastatic lesions seems to be expectedly
associated with improved survival. However, the role and impact of peritumoral immune
infiltration and inflammation status in liver parenchyma and their impact on prognosis
are yet to be discovered. There is evidence that certain immune patterns are associated
with certain HGPs. The HGP may be one of the key factors sculpting the development of
certain immune phenotypes of LM-CRC. Further studies using standardized evaluation
and reporting systems are needed to confirm and clarify such association.
4. Clinical Opportunities of TME in the Context of the HGP
LM-CRC are a defiance for cancer treatment, since they are entities that have the
particularity of recruiting a large number of cells with an immunosuppressive capacity
and, even more challenging, that have characteristic resistance to a multitude of antitumor
drugs, aspects very well summarized in Ciner AT et al. [99].
However, the particular pathological and histological characteristics of the TME in
hepatic metastases, as well as the particular biology of the different phenotypes, are the
aspects that could be exploited clinically. We have already commented that HGPs have a
prognostic and predictive value, although prospective studies are warranted to validate this.
Thus, knowing the HGP prior to surgery, i.e., being able to determine metastases with an
established capsule, could contribute to the better selection of patients for a curative surgical
resection. Knowing the HGP at the pre-operative stage could improve patient selection
for neoadjuvant treatment, minimizing the toxicity effects and surgery-related risks. This
fact could be approached by using modern medical imaging techniques and is extensively
reviewed by Oliveira RC et al. and Latacz E et al. [21,85]. Radiomics is another powerful
non-invasive tool capable of classifying tumors at the morphological [100] and molecular
levels [101]. Thus, in a retrospective study, Cheng et al. used pre- and post-contrast (arterial
and portal venous) phase MDCT images to build a radiomic classifier which predicted the
HGP with remarkable accuracy [102]. According to the authors, they could distinguish a
clear tumor–liver interface in the tumors with a dHGP and fibrotic capsule, while a poorly
defined tumor–liver interface would be associated with a replacement growth pattern.
Another important feature of liver metastases, linked to the HGP, is the type of
vascularization which the tumor develops. As we described above, two vascularization
strategies, i.e., vessel co-option (in tumors with a replacement HGP) or neoangiogenesis
(in tumors with a dHGP), can be clearly distinguished. In this regard, patients whose
metastases have a desmoplastic HGP would be candidates for receiving anti-angiogenics
drugs in neoadjuvant settings. Non-invasive imaging for the classification of the HGP is
the pre-requisite for such therapeutic approach.
Another opportunity relies on the observation that regardless of the HGP, LM-CRC are
characterized by some degree of immune suppression, at least in central areas of the tumor
lesion, as above reviewed. However, anti-angiogenic [103] and anti-fibrotic [104–107] ther-
apies could be interesting strategies to re-establish the anti-tumoral immunity and are thus
direct targets of immunotherapeutic approaches. Current clinical trials are assessing this hy-
pothesis (NCT03698461), although no criteria for selection of patients according to the HGP
have been applied. However, some caution must be exercised since some approaches have
turned out to be counterproductive and report the opposite observation [108], especially if
they are not accompanied by ICI.
The counterproductive results obtained so far using the deletion or silencing of particu-
lar mesenchymal cells raise the question for different CAF subsets, as stated throughout the
text. This fact is especially relevant in the context of HGPs and taking into account different
potential precursors of CAFs in the liver. It could be hypothesized that the fibroblasts that
form the capsule are different from those that are located in the central regions of the tumor.
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Thus, the fibroblasts that form the fibrotic rim may exert a protective role by enveloping the
tumor and hindering the invasion into the liver tissue. The capsule in the dHGP may have
certain similarities to the peritumoral host reaction against benign tumors or abscesses.
Thus, these observations open the door for researchers in the field to try to reprogram
intratumoral fibroblasts. We usually find these cells in large numbers in rHGP metastases
but also in dHGP metastases. However, intratumoral CAFs in invasive versus central
deeper areas could probably be performing different functions. The conceptual idea is
to differentiate those CAFs into fibroblasts that would have the ability to envelop, as a
shield or shell, the tumor itself, preventing the spreading of the tumor inside the liver
plates. Reprogramming fibroblasts has been a successful strategy at the preclinical level
so far. As in all organs, resident mesenchymal cells are transformed into CAFs due to the
selective pressures exerted by the tumor–stroma crosstalk. In pancreatic cancer, as well
as in pancreatitis, pancreatic stellate cells (PSC) are differentiated to CAFs. In this process
of loss of quiescence, they lose the expression of the vitamin D receptor, a fact that has
been reversed by administering synthetic derivatives of vitamin D such as calcipotriol,
inducing quiescence in the CAFs, and, in turn, the reestablishment of the transcriptional
programs of the PSC [109]. In the same vein, all-trans retinoic acid (ATRA), the active
metabolite of vitamin A, is able to restore quiescence of PSC by means of a reduction in the
myofibroblastic properties of activated PSC, a process involving RARβ [110]. However,
it is still a matter of major concert determining which is the trigger that induces the
encapsulating response. Is it a host response or tumor-driven?
Thus, the particular histology of colorectal carcinoma liver metastases, conditioned by
the characteristics of the TME, should be taken into account when designing therapeutic
clinical trials and could be known in advance using conventional medical imaging techniques.
5. Conclusions
Thus, as final thoughts and comments, LM-CRC are tumors that have particular
characteristics in terms of their content in TME cells, both qualitatively and quantitatively.
This fact makes them distinct entities with respect to their corresponding primary tumors.
Furthermore, this fact should have an impact on the way we treat metastases. However,
treatments have not been designed according to these particularities so far. Be that as it
may, we need to better understand the particularities of the cells that form the TME in
each particular location, since we already know that, e.g., fibroblasts display anatomic
demarcation that affects their transcriptional repertoire.
All these facts acquire even greater relevance since LM-CRC present different HGPs,
having a great impact on the way the stroma is organized. In this sense, the new spatial
transcriptomic technologies can contribute to improving such knowledge. However, much
more affordable and feasible technologies could also contribute with relevant clinical
answers. The prospective assessment of the HGP is needed in terms of reinforcing the
prognostic and predictive value described so far. Further, it would be highly recommended
to include such feasible assessment in the pathological anatomy reports on a routine
basis. Furthermore, having this information available prior to surgery could, on the one
hand, help design more efficient neoadjuvant treatments for those resectable patients and,
on the other hand, be able to offer potentially curative strategies to those initially non-
surgical patients. This clinical information can only be obtained through medical imaging
techniques, and there are different initiatives underway to demonstrate the feasibility
of this option. However, in order to obtain a clinical benefit with an impact on affected
patients, it is necessary to deepen the knowledge of the biology of HGPs. We still do
not know with certainty which is the cause that motivates the formation of the capsules.
However, it would be of great interest to be able to pharmacologically induce the formation
of such fibrotic capsules. In any case, the combination of both better knowledge and routine
assessment by means of medical imaging would have an impact on the selection of patients
for personalized treatments, particularly relevant for the majority of patients that could not
benefit from a potentially curative resection.
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